Table 1.

Clinical features of patients infected with HAdV-55 or HAdV-7 in this study

	HAdV55 (n = 8)	HAdV7 (n = 32)	P
Age (yrs)	0.73 ± 0.78	2.48 ± 3.06	0.120
Male (%)	5/8 (63%)	26/32 (81%)	0.256
Any underlying diseases	0	2/32	0.529
Symptoms and signs
Fever≥38 °C	7/7 a (100%)	32/32 (100%)	/
Maximum temperature (°C)	39.41 ± 0.94b	39.79 ± 0.64	0.161
Duration of fever (days)	14.5 ± 10.75b	15.14 ± 5.48	0.960
Cough	6/6b (100%)	32/32 (100%)	/
Rhinorrhea	2/6b (33%)	4/32 (13%)	0.199
Wheezing	1/6b (17%)	20/32 (63%)	0.038c
Swelling of tonsils	4/6b (67%)	13/32 (41%)	0.239
Rash	2/6b (33%)	5/32 (16%)	0.305
Vomiting	0b	3/32 (9%)	0.435
Diarrhea	1/6b (17%)	11/32 (34%)	0.392
Dyspnea	2/6b (33%)	10/32 (31%)	0.920
Lung infiltrates	4/6b (67%)	16/32 (50%)	0.453
Complicationd	2/7a (29%)	18/32 (56%)	0.184
Laboratory detection
WBC (109/L)	11.48 ± 3.08a	10.64 ± 5.71	0.709
Neutrophil %	63.20% ± 15.03%a	57.98% ± 17.46%	0.469
Lymphocyte %	29.26% ± 12.53%a	35.25% ± 17.59%	0.402
Platelet (109/L)	274.71 ± 184.61a	291.29 ± 146.87	0.801
CRP (mg/L)	26.53 ± 24.84a	33.42 ± 45.86	0.706
Treatment
ICU admission	1/7a (14%)	5/32 (16%)	0.929
Mechanical ventilation	1/6b (17%)	9/32 (28%)	0.559
Immunoglobulin	2/7a (29%)	17/32 (53%)	0.239
Length of hospital stay (days)	11.33 ± 6.86b	19.10 ± 10.41	0.109
Clinical scoree	6.43 ± 2.44a	8.21 ± 2.98	0.148

Note:

^aOne subject was an outpatient, and information about this subject was not documented

^bThere was a patient (other than the aforementioned outpatient) who left hospital in advance and without recovery, and her clinical features (except for the first blood test after admission to hospital) could not be documented

^cStatistically significant (P < 0.05)

^dComplications include respiratory failure, cardiac damage, or liver function damage

^eA clinical scoring system for ALRTIs was used to assess severity of illness on the day of enrollment